Gastric cancer in Latin America

Ruiz‐García, Erika; Guadarrama-Orozco, Jorge Alberto; Vidal-Millán, Silvia; Lino-Silva, Leonardo S.; López-Camarillo, César; Vega, Horacio Astudillo‐de la

doi:10.1080/00365521.2017.1417473

Cited by 13 publications

(13 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Helicobacter pylori (Hp) is the key risk factor for stomach cancer and the prevalence of Hp is comparatively high in LA . Diet rich in red meat, processed meat, salt and chili pepper, widespread in several countries considered, is associated to stomach cancer, too . In addition, tobacco smoking increases the risk of this neoplasm .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer mortality predictions for 2019 in Latin America

Carioli

Bertuccio

Malvezzi

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

We estimated mortality figures for 2019 in seven Latin American countries, with focus on breast cancer. We retrieved cancer death certification and population data from the WHO and PAHO databases. We obtained mortality statistics for Argentina, Brazil, Chile, Colombia, Cuba, Mexico and Venezuela for 1970-2015. We predicted current death numbers and agestandardised (world population) mortality rates using joinpoint regression models. Total cancer mortality is predicted to decline in all countries and both sexes, except Argentinian women. Cuba had the highest all cancer rates for 2019, 136.9/100,000 men and 90.4 women, while Mexico showed the lowest ones, 63.8/100,000 men and 61.9 women. Stomach cancer showed favourable trends over the whole period, while colorectal cancer only recently. Lung cancer rates declined in men, while in women they decreased slightly over the most recent years, only. In Cuban women, lung cancer rates overtook breast cancer ones. Breast cancer showed overall favourable trends, but rates are rising in young women. Prostate and uterine cancer had favourable trends. Pancreas, ovary, bladder and leukaemias showed slightly decreasing trends. Between 1990 and 2019, mortality from all neoplasms is predicted to fall by about 18% in Argentina, 26% in Chile, 14% in Colombia, 17% in Mexico and 13% in Venezuela, corresponding to almost 0.5 million avoided cancer deaths. No decline was observed in Brazil and Cuba. Of concern, the persisting high rates of (cervix) uterus cancer, the high lung cancer rates in Cuba, the possible increases in breast cancer in young women, and the lack of overall declines in Brazil, Cuba and Venezuelan men. Materials and MethodsWe obtained official deaths certification data from the World Health Organization (WHO) database 10 for all cancers combined and for 10 major cancer types, i.e., stomach, colorectum, pancreas, lung, breast, uterus (cervix and corpus), ovary, prostate, bladder and leukaemias. We retrieved data for the period between 1970 and 2015 for LA countries with over Additional Supporting Information may be found in the online version of this article.

show abstract

Section: Discussionmentioning

confidence: 99%

“…In addition, tobacco smoking increases the risk of this neoplasm . Late stage at diagnosis and delay in treatments could also explain the high mortality rates …”

Section: Discussionmentioning

confidence: 99%

Cancer mortality predictions for 2019 in Latin America

Carioli

Bertuccio

Malvezzi

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…This might reflect the higher incidence of these cancers in Asian populations. However, the increased burden of gastric cancer in Latin America (155,156) suggests that better representation outside of East Asian origin will be important.…”

Section: Distribution Of Genetic Ancestry Of Cancer Cell Linesmentioning

confidence: 99%

An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines

et al. 2019

View full text Add to dashboard Cite

Recent work points to a lack of diversity in genomics studies from genome-wide association studies to somatic (tumor) genome analyses. Yet, population-specific genetic variation has been shown to contribute to health disparities in cancer risk and outcomes. Immortalized cancer cell lines are widely used in cancer research, from mechanistic studies to drug screening. Larger collections of cancer cell lines better represent the genomic heterogeneity found in primary tumors. Yet, the genetic ancestral origin of cancer cell lines is rarely acknowledged and often unknown. Using genome-wide genotyping data from 1,393 cancer cell lines from the Catalogue of Somatic Mutations in Cancer (COSMIC) and Cancer Cell Line Encyclopedia (CCLE), we estimated the genetic ancestral origin for each cell line. Our data indicate that cancer cell line collections are not representative of the diverse ancestry and admixture characterizing human populations. We discuss the implications of genetic ancestry and diversity of cellular models for cancer research and present an interactive tool, Estimated Cell Line Ancestry (ECLA), where ancestry can be visualized with reference populations of the 1000 Genomes Project. Cancer researchers can use this resource to identify cell line models for their studies by taking ancestral origins into consideration.

show abstract

“…Within South America, mortality rates range from 3.6 to 23.6 per 100,000/year. In Chile, GC is the leading cause of cancer death with 25.1 and 13.2 per 100,000/year for men and women, respectively [2,3]. Although several factors may explain this scenario, most studies suggest that high mortality rate can be attributed to late diagnosis, due to slow-growing asymptomatic tumors.…”

Section: Introductionmentioning

confidence: 99%

High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study

Córdova-Delgado

Pinto

Retamal

et al. 2019

Cancers

View full text Add to dashboard Cite

Gastric cancer (GC) is a heterogeneous disease. This heterogeneity applies not only to morphological and phenotypic features but also to geographical variations in incidence and mortality rates. As Chile has one of the highest mortality rates within South America, we sought to define a molecular profile of Chilean GCs (ClinicalTrials.gov identifier: NCT03158571/(FORCE1)). Solid tumor samples and clinical data were obtained from 224 patients, with subsets analyzed by tissue microarray (TMA; n = 90) and next generation sequencing (NGS; n = 101). Most demographic and clinical data were in line with previous reports. TMA data indicated that 60% of patients displayed potentially actionable alterations. Furthermore, 20.5% were categorized as having a high tumor mutational burden, and 13% possessed micro-satellite instability (MSI). Results also confirmed previous studies reporting high Epstein-Barr virus (EBV) positivity (13%) in Chilean-derived GC samples suggesting a high proportion of patients could benefit from immunotherapy. As expected, TP53 and PIK3CA were the most frequently altered genes. However, NGS demonstrated the presence of TP53, NRAS, and BRAF variants previously unreported in current GC databases. Finally, using the Kendall method, we report a significant correlation between EBV+ status and programmed death ligand-1 (PDL1)+ and an inverse correlation between p53 mutational status and MSI. Our results suggest that in this Chilean cohort, a high proportion of patients are potential candidates for immunotherapy treatment. To the best of our knowledge, this study is the first in South America to assess the prevalence of actionable targets and to examine a molecular profile of GC patients.

show abstract

Gastric cancer in Latin America

Cited by 13 publications

References 59 publications

Cancer mortality predictions for 2019 in Latin America

Cancer mortality predictions for 2019 in Latin America

An Interactive Resource to Probe Genetic Diversity and Estimated Ancestry in Cancer Cell Lines

High Proportion of Potential Candidates for Immunotherapy in a Chilean Cohort of Gastric Cancer Patients: Results of the FORCE1 Study

Contact Info

Product

Resources

About